NADAC acquisition cost data for CIMETIDINE 400 MG TABLET. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00093820401 | $0.4232 | 2022-12-21 | Rx |
| 00093820405 | $0.4232 | 2022-12-21 | Rx |
| 00378037201 | $0.4232 | 2022-12-21 | Rx |
| 00093820401 | $0.4232 | 2022-12-21 | Rx |
| 00093820405 | $0.4232 | 2022-12-21 | Rx |
| 00378037201 | $0.4232 | 2022-12-21 | Rx |
Generic: Cimetidine | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $1.9M | 36,260 | 17,368 | $0.7123 |
| 2020 | $11.3M | 189,039 | 62,391 | $0.7934 |
| 2021 | $10.0M | 160,677 | 42,938 | $0.7697 |
| 2022 | $8.2M | 125,615 | 33,605 | $0.7785 |
| 2023 | $7.8M | 113,633 | 29,869 | $0.8208 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| Ohio | $642.7K | 10,411 | 2,048 |
| California | $601.3K | 6,899 | 2,271 |
| New York | $521.1K | 7,956 | 1,896 |
| Florida | $411.0K | 5,990 | 2,130 |
| Pennsylvania | $401.9K | 6,224 | 1,407 |
| Tennessee | $395.6K | 5,255 | 1,369 |
| Texas | $365.6K | 5,424 | 1,815 |
| Michigan | $287.4K | 3,651 | 1,095 |
| Indiana | $227.0K | 3,456 | 835 |
| Missouri | $214.7K | 2,693 | 650 |
| North Carolina | $211.8K | 3,048 | 839 |
| Kentucky | $186.0K | 3,318 | 825 |
| Georgia | $183.8K | 2,728 | 824 |
| Illinois | $175.4K | 2,399 | 669 |
| Alabama | $174.4K | 2,415 | 742 |
| Wisconsin | $174.2K | 2,096 | 526 |
| Minnesota | $159.8K | 2,230 | 534 |
| West Virginia | $154.5K | 3,046 | 591 |
| Puerto Rico | $151.5K | 4,522 | 996 |
| Iowa | $136.4K | 1,848 | 413 |
| Washington | $133.5K | 1,514 | 411 |
| Virginia | $132.4K | 2,135 | 546 |
| Massachusetts | $130.2K | 1,669 | 485 |
| Arizona | $127.7K | 1,493 | 447 |
| South Carolina | $126.9K | 1,964 | 640 |
| Oregon | $126.2K | 1,542 | 364 |
| Maryland | $102.4K | 1,382 | 409 |
| Maine | $95.0K | 1,013 | 290 |
| Louisiana | $90.4K | 2,062 | 704 |
| Colorado | $87.8K | 986 | 293 |
| Oklahoma | $86.8K | 1,228 | 310 |
| New Jersey | $77.7K | 1,048 | 337 |
| Arkansas | $75.3K | 1,173 | 344 |
| New Mexico | $73.5K | 730 | 247 |
| Kansas | $66.8K | 1,276 | 250 |
| Mississippi | $58.4K | 1,234 | 325 |
| Utah | $53.8K | 667 | 200 |
| Connecticut | $52.9K | 587 | 163 |
| Idaho | $42.2K | 699 | 169 |
| Nebraska | $41.5K | 534 | 115 |
| Nevada | $24.3K | 419 | 138 |
| Rhode Island | $23.9K | 323 | 77 |
| Hawaii | $22.5K | 354 | 136 |
| New Hampshire | $21.9K | 379 | 106 |
| Vermont | $19.0K | 202 | 56 |
| Delaware | $15.7K | 233 | 71 |
| Montana | $15.3K | 354 | 105 |
| South Dakota | $14.6K | 298 | 50 |
| North Dakota | $11.5K | 194 | 61 |
| District of Columbia | $9.2K | 113 | 44 |
| Pennsylvania | $5.9K | 61 | 13 |
| Wyoming | $5.3K | 69 | 19 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.